Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 12, 2025 • 12:00 AM ET

Date/Time Source News Release
01/09/2025 08:04 AM EST PR Newswire INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
12/13/2024 07:00 AM EST PR Newswire INOVIO Announces Pricing of $30 Million Public Offering
12/12/2024 04:01 PM EST PR Newswire INOVIO Announces Proposed Public Offering
12/03/2024 08:00 AM EST PR Newswire New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
11/29/2024 04:02 PM EST PR Newswire INOVIO Reports Inducement Grant Under Inducement Plan
11/14/2024 04:05 PM EST PR Newswire INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/13/2024 08:00 AM EST PR Newswire Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
11/06/2024 04:05 PM EST PR Newswire INOVIO to Present at Upcoming Scientific Conferences
11/06/2024 08:00 AM EST PR Newswire INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
10/21/2024 08:00 AM EDT PR Newswire INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
Page